Edition:
India

Fresenius SE & Co KGaA (FREG.DE)

FREG.DE on Xetra

45.03EUR
19 Jul 2019
Change (% chg)

€-0.29 (-0.65%)
Prev Close
€45.33
Open
€45.50
Day's High
€45.69
Day's Low
€44.21
Volume
1,865,915
Avg. Vol
1,643,525
52-wk High
€71.00
52-wk Low
€38.28

Latest Key Developments (Source: Significant Developments)

U.S. FDA Says Fresenius Kabi USA Issues Voluntary Nationwide Recall Of Two Lots Of Fluorouracil Injection
Wednesday, 3 Jul 2019 

July 2 (Reuters) - U.S. Food and Drug Administration::U.S. FDA SAYS FRESENIUS KABI USA ISSUES VOLUNTARY NATIONWIDE RECALL OF TWO LOTS OF FLUOROURACIL INJECTION DUE TO THE POTENTIAL FOR GLASS PARTICULATE.  Full Article

S&P Upgrades Fresenius To BBB With Stable Outlook -Statement
Thursday, 23 May 2019 

May 23 (Reuters) - Fresenius SE & Co KGaA ::S&P UPGRADES FRESENIUS TO BBB WITH STABLE OUTLOOK.  Full Article

Fresenius Medical Care Says A Large Shareholder Majority Approved Consecutive Dividend Increase
Thursday, 16 May 2019 

May 16 (Reuters) - FRESENIUS MEDICAL CARE ::FRESENIUS MEDICAL CARE - A LARGE SHAREHOLDER MAJORITY OF 89.78 PERCENT APPROVED COMPANY'S 22ND CONSECUTIVE DIVIDEND INCREASE.FRESENIUS MEDICAL CARE - DIVIDEND WILL BE RAISED FROM EUR 1.06 TO EUR 1.17, AN INCREASE OF 10 PERCENT.  Full Article

Fresenius Medical Care Confirms 2019 Outlook After Q1
Thursday, 2 May 2019 

May 2 (Reuters) - Fresenius Medical Care ::CONFIRMS OUTLOOK FOR 2019, EFFECTS FROM PLANNED TAKEOVER OF NXSTAGE MEDICAL INC NOT TAKEN INTO ACCOUNT.Q1 ADJUSTED REVENUE 4.13 BILLION EUR (VERSUS. 3.73 BILLION IN PREV YEAR).Q1 ADJUSTED EBIT 551 MILLION EUR (VERSUS. 506 MILLION IN PREV YEAR).Q1 ADJUSTED NET PROFIT 318 MILLION EUR (VERSUS. 296 MILLION IN PREV YEAR).  Full Article

Akorn Comments On Fresenius’ Proposed Amended Claims
Thursday, 21 Feb 2019 

Feb 20 (Reuters) - Akorn Inc ::AKORN COMMENTS ON FRESENIUS’ PROPOSED AMENDED CLAIMS.AKORN INC - BELIEVES FRESENIUS' PROPOSED AMENDED CLAIMS "MERITLESS AND OVERREACHING", DENIES ALLEGATIONS.  Full Article

Fresenius Sees Break-Even Point In Biosimilars Business In 2022
Wednesday, 20 Feb 2019 

Feb 20 (Reuters) - Fresenius SE & Co KGaA CEO::WE EXPECT BREAK-EVEN IN BIOSIMILARS BUSINESS ROUGHLY IN 2022.FAILED AKORN TAKEOVER HAS SO FAR COST US HIGH DOUBLE-DIGIT MILLION AMOUNT.  Full Article

Fresenius CEO Says Our Portfolio Is Not Set In Stone
Wednesday, 20 Feb 2019 

Feb 20 (Reuters) - Fresenius SE & Co KGaA ::CEO - CAN'T RULE OUT THAT WE WILL DISPOSE OF SOME CLINICS IN OUR HOSPITALS BUSINESS.CEO SAYS OUR PORTFOLIO IS NOT SET IN STONE.  Full Article

Fresenius Kabi Says Received 510(K) Clearance From U.S. FDA For Fenwal Amicus Red Blood Cell Exchange (Rbcx) System
Friday, 15 Feb 2019 

Feb 15 (Reuters) - FRESENIUS KABI: :FRESENIUS KABI - RECEIVED 510(K) CLEARANCE FROM U.S. FDA FOR FENWAL AMICUS(®) RED BLOOD CELL EXCHANGE (RBCX) SYSTEM.  Full Article

Akorn CEO Raj Rai to leave after court ruling against co
Saturday, 8 Dec 2018 

Dec 7 (Reuters) - Akorn Inc ::SUPREME COURT OF THE STATE OF DELAWARE RULES AGAINST AKORN, NEW CEO SEARCH UNDERWAY.AKORN INC - CURRENT CEO RAJ RAI HAS DECIDED TO RETIRE.AKORN - AKORN'S BOARD ANNOUNCED THAT IT IS ENGAGED IN A FORMAL SEARCH FOR A NEW CHIEF EXECUTIVE OFFICER TO LEAD COMPANY INTO ITS NEXT PHASE.AKORN INC - CEO RAJ RAI WILL ASSIST BOARD TO ENSURE A SMOOTH TRANSITION AND REMAIN IN HIS ROLE UNTIL HIRING DATE OF NEW CHIEF EXECUTIVE.AKORN INC - HAS RECEIVED SEVERAL NEW ABBREVIATED NEW DRUG APPLICATION APPROVALS FROM FOOD AND DRUG ADMINISTRATION.  Full Article

Fresenius Costs Related To Akorn Total 60 Mln Euros So Far - CEO
Friday, 18 May 2018 

May 18 (Reuters) - Fresenius CEO at Annual General Meeting::CEO SAYS COSTS RELATED TO AKORN <<>> TRANSACTION TOTAL 60 MILLION EUROS SO FAR.SAYS MUST EXAMINE WHETHER PROVISIONS NEED TO BE SET ASIDE IN CONNECTION WITH AKORN.FRESENIUS CEO SAYS HAVE FILED FOR SUFFICIENT LEVEL OF DAMAGES FROM AKORN.  Full Article

Photo

Fresenius says tighter EU rules could trigger antibiotic shortage

FRANKFURT German drugmaker Fresenius warned that stricter production norms being considered by Europe's drug regulator could compound shortages of a life-saving antibiotic that is used by about 25 million patients globally each year.